

MEDIA RELEASE • MEDIENMITTEILUNG • COMMUNIQUE AUX MEDIAS

Harry Welten becomes new CFO at Cytos Biotechnology Ltd

Schlieren (Zurich), Switzerland, April 30, 2010 – Cytos Biotechnology Ltd (SIX:CYTN) announced that the longtime chief financial officer Jakob Schlapbach wishes to make use of the option of early retirement from his operational role.

The Board appointed Mr. Harry Welten as his successor. Harry Welten will begin at 1 June 2010 and take over after a short familiarization phase the role of CFO of Jakob Schlapbach.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology: "We thank Jakob Schlapbach for his 10 years as CFO at Cytos Biotechnology. Jakob Schlapbach has done all financial transactions since 2000, particularly the IPO, when Cytos Biotechnology listed on the Swiss stock exchange after the acquisition of Askliia Holding AG. We wish him all the best for the future and are pleased that he will bring his experience to the Board of directors as a member."

Harry Welten has many years of international professional and transaction experience. Recently Harry Welten was CFO during the merger of the company Nitec Pharma AG with the American firm Horizon Pharma AG. Previously, he served for nine years at the company Arpida AG as CFO and was responsible among other things, for the listing on the Swiss stock exchange in 2005.

Harry Welten: "I am very happy that I can use my knowledge at Cytos Biotechnology. I am convinced that I can bring my many years of experience as a CFO in the life science industry and relationships with investors to support Cytos Biotechnology."

Dr. Wolfgang Renner: "We are proud to have attracted Harry Welten, an experienced financial expert with a long standing track record in the biotech industry as a CFO. Harry, thanks to his previous activities as CFO of Arpida AG and Nitec Pharma AG has a wide network of relationships with investors and analysts. We welcome Harry Welten and wish him a good start."

For further information please contact:

Dr. Wolfgang A. Renner
Chief Executive Officer
Cytos Biotechnology AG
Tel: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner@cytos.com
Website: www.cytos.com

About Cytos Biotechnology

Cytos Biotechnology Ltd is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug™ platform, Cytos Biotechnology has built a diversified pipeline of Immunodrug™ candidates in various disease areas, of which six are currently in clinical development. The Immunodrug™ candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Currently, the Company has 81 full-time employees. Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

This foregoing press release may contain forward-looking statements that include words or phrases such as “will”, “are intended for”, “are designed to” or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.